13F Portfolios

Lynx1 Capital Management LP: DENALI THERAPEUTICS INC (DNLI): Quarterly 13F Position History

As of Q1 2026, Lynx1 Capital Management LP reported 1,880,303 shares of DENALI THERAPEUTICS INC (DNLI), worth $36.1M and representing 5.7% of its 13F equity book. Quarter-over-quarter share count change: + 141,553 (+8.1%) . The position first appeared in Q3 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 1,880,303 +141,553 +8.1% $36.1M 5.7% $19.2
Q4 2025 1,738,750 +1,477,063 +564.4% $28.7M 5.8% $16.5
Q3 2025 261,687 $3.8M 0.8% $14.5

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Lynx1 Capital Management LP first disclose a DNLI position in 13F-HR filings?

Lynx1 Capital Management LP first reported DENALI THERAPEUTICS INC (DNLI) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.

What was Lynx1 Capital Management LP's most recent quarter-over-quarter share-count change in DNLI?

Between Q4 2025 and Q1 2026, Lynx1 Capital Management LP added 141,553 shares of DNLI (+8.1%), bringing the total reported position to 1,880,303 shares at a market value of $36.1M.

Does the implied price-per-share represent Lynx1 Capital Management LP's cost basis in DNLI?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.